Blood-test manufacturers are preparing to change the way Alzheimer’s disease is diagnosed with a nearing blockbuster treatment for millions of Americans, Bloomberg’s Robert Langreth reports. Even doctors who were initially concerned about tests for Alzheimer’s are gaining confidence that products from Quest Diagnostics (DGX), Quanterix (QTRX) and C2N Diagnostics can aid in determining which patients may qualify for treatment with the experimental drug lecanemab, set to be approved next year. Reference Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DGX:
- Quest Diagnostics price target raised to $165 from $160 at Mizuho
- Quest Diagnostics partners with Northern Light Health in Maine
- Quest Diagnostics awarded group purchasing agreement by Premier
- Quest Diagnostics Completes Acquisition of Outreach Lab Services Business of Summa Health
- Quest Diagnostics completes acquisition of LabCare